CNBX Pharmaceuticals Inc. (CNBX)
OTCMKTS · Delayed Price · Currency is USD
0.0004
+0.0001 (16.67%)
Nov 4, 2025, 4:00 PM EST
CNBX Pharmaceuticals Revenue
In the fiscal year ending August 31, 2024, CNBX Pharmaceuticals had annual revenue of $130.07K, down -68.29%.
Revenue
130.07K
Revenue Growth
-68.29%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
2
Market Cap
263.62K
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Aug 31, 2024 | 130.07K | -280.09K | -68.29% |
| Aug 31, 2023 | 410.17K | 380.21K | 1,269.13% |
| Aug 31, 2022 | 29.96K | - | - |
| Aug 31, 2021 | - | - | - |
| Aug 31, 2020 | 7.16K | -2.69K | -27.29% |
| Aug 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Jushi Holdings | 256.36M |
| Glass House Brands | 221.55M |
| Elite Pharmaceuticals | 105.45M |
| Silence Therapeutics | 27.17M |
| China New Energy Group Co. | 12.51M |
| Northwest Biotherapeutics | 1.09M |
CNBX Pharmaceuticals News
- 3 years ago - Cannabis REITs: Smoked Out - Seeking Alpha
- 3 years ago - CNBX to Enter the Cancer Immunotherapy Market After Acquiring a Controlling Interest in TaGeza Biopharma - PRNewsWire
- 3 years ago - CNBX Files New PCT Patent Application For Cannabinoids-Based Neoadjuvant Cancer Therapy - PRNewsWire
- 3 years ago - CNBX Patent Application "Composition and Method for Treating Cancer with Cannabinoids" Enters National Phase in US and Israel - PRNewsWire
- 3 years ago - CNBX Peer-reviewed Study: "Possible Future Therapeutic Value" for CNBX Proprietary Drug Candidate - PRNewsWire
- 3 years ago - CNBX Pharmaceuticals Announces New Patent Granted in Australia - PRNewsWire
- 3 years ago - CNBX Pharmaceuticals Granted Patent in Hong Kong - PRNewsWire
- 3 years ago - Cannabics Pharmaceuticals Changes Name to CNBX Pharmaceuticals - PRNewsWire